The researchers used data from 139 patients with biopsy-driven NAFLD. All the biopsies were re-classified according to the SAF scoring system, with the diseases defined as mild, moderate or severe via an index combining activity and fibrosis. Patients were followed up for an average of 26 years.
Here are three points:
1. At baseline, 69 patients had a severe form of the disease and 35 patients had mild or moderate disease.
2. Of the 70 patients who died during follow-up, 59 percent came from those previously classified as having a severe form of NAFLD.
3. NAFD is the most common liver disease worldwide, affecting more than 20 percent of the worldwide population.
More articles on GI & endoscopy:
Olympus launches enhanced GI benchmarking product, HCSC issues coverage for Torax Medical’s LINX system & more — 5 GI company key notes
Mercy Health names Dr. Anton Decker chief clinical officer: 3 things to know
Gastroenterologist to know: Dr. Gary Matusow of Gastroenterology Group & Endoscopy Center of South Jersey
